Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sotera Health (SHC) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Sotera Health (SHC) over the last 5 years, with Sep 2025 value amounting to $299.2 million.

  • Sotera Health's Cash & Equivalents fell 2.46% to $299.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.2 million, marking a year-over-year decrease of 2.46%. This contributed to the annual value of $277.2 million for FY2024, which is 6.47% down from last year.
  • Sotera Health's Cash & Equivalents amounted to $299.2 million in Q3 2025, which was down 10.00% from $332.4 million recorded in Q2 2025.
  • Sotera Health's Cash & Equivalents' 5-year high stood at $647.9 million during Q1 2023, with a 5-year trough of $106.9 million in Q4 2021.
  • Its 3-year average for Cash & Equivalents is $316.3 million, with a median of $296.4 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 433.55% in 2023, then crashed by 59.70% in 2024.
  • Quarterly analysis of 5 years shows Sotera Health's Cash & Equivalents stood at $106.9 million in 2021, then spiked by 269.65% to $395.2 million in 2022, then fell by 25.00% to $296.4 million in 2023, then fell by 6.47% to $277.2 million in 2024, then fell by 2.46% to $299.2 million in 2025.
  • Its Cash & Equivalents was $299.2 million in Q3 2025, compared to $332.4 million in Q2 2025 and $304.4 million in Q1 2025.